US Patent

US11571436 — Oral formulations of cytidine analogs and methods of use thereof

Formulation · Assigned to Celgene Corp · Expires 2029-05-14 · 3y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects oral formulations of cytidine analogs that release the active ingredient substantially in the stomach.

USPTO Abstract

The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

Drugs covered by this patent

Patent Metadata

Patent number
US11571436
Jurisdiction
US
Classification
Formulation
Expires
2029-05-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.